Ruxolitinib enhances gastric cancer to chemotherapy by suppressing JAK/STAT3 and inducing mitochondrial dysfunction and oxidative stress. - Yao, Yang; Zhou, Jun; Song, Jing; Chen, Cheng (Immunopharmacology & Immunotoxicology, 2025)